Lisocabtagene maraleucel is an anti-CD19 CAR-T cell therapy commercially known as BREYANZITM for the treatment of adult patients with LBCL, r/r lymphocytic leukemia (r/r CLL) or small lymphocytic lymphoma (r/r SLL), r/r FL, and r/r MCL (51). Here, CD19 is linked to B-cell chronic lymphocytic leukemia.